Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A congenital myasthenic syndrome characterized by defects in postsynaptic neuromuscular junctions with early-onset progressive muscle weakness that has material basis in mutation in the CHRNA1 gene on chromosome 2q.
Features include always present findings: Limb muscle weakness, Weakness of facial musculature, EMG: decremental response of compound muscle action potential to repetitive nerve stimulation, and Easy fatigability and others. 27 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 11 | Type 2 muscle fiber atrophy, Low muscle tone (hypotonia), Limb muscle weakness |
CHRNA1 encodes cholinergic receptor nicotinic alpha 1 subunit (457 aa). Upon acetylcholine binding, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane Highest expression in Muscle Skeletal (29.9 TPM) and Pituitary (1.9 TPM).
Myasthenic syndrome, congenital, 1B, fast-channel is associated with mutations in the CHRNA1 gene on chromosome 2.
The CHRNA1 protein participates in CHRNA9:CHRNA10:AcCho transports Ca2+ from the extracellular region to the cytosol pathway.
CHRNA1 is classified as a druggable target (Cell Surface, Druggable Genome, and Ion Channel categories) with score 2.5.
Genetic testing for CHRNA1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for myasthenic syndrome, congenital, 1B, fast-channel has been reported in the published literature.
Phenotype severity distribution: 5 always present features.
No clinical trials have been registered for myasthenic syndrome, congenital, 1B, fast-channel.
4 publications have been identified in PubMed for myasthenic syndrome, congenital, 1B, fast-channel. Research spans Basic Science / Preclinical (50%), Diagnostic / Biomarker (25%), and Epidemiology / Natural History (25%).
Littel HR (2026). [PMID: 40944391](https://pubmed.ncbi.nlm.nih.gov/40944391/). *FEBS open bio*. [Basic Science / Preclinical]
Ham AS (2025). [PMID: 40044687](https://pubmed.ncbi.nlm.nih.gov/40044687/). *Nature communications*. [Basic Science / Preclinical]
Ryan-Phillips F (2024). [PMID: 39595115](https://pubmed.ncbi.nlm.nih.gov/39595115/). *Biomedicines*. [Diagnostic / Biomarker]
Theuriet J (2024). [PMID: 38696726](https://pubmed.ncbi.nlm.nih.gov/38696726/). *Brain : a journal of neurology*. [Epidemiology / Natural History]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 5:38 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Head and neck |
3 |
Facial palsy, Weakness of facial musculature, High palate |
Brain and nerves | 2 | Difficulty swallowing (dysphagia), Dysarthria |
Arms and legs | 1 | Limb muscle weakness |
Digestive system | 1 | Difficulty swallowing (dysphagia) |
Bones and joints | 1 | Sideways curvature of the spine (scoliosis) |
Lab test results | 1 | Anti-neuromuscular Junction acetylcholine receptor antibody positivity |
Eyes | 1 | Ptosis |
Pregnancy and birth | 1 | Neonatal hypotonia |
Lungs and breathing | 1 | Difficulty breathing due to muscle weakness (respiratory insufficiency due to muscle weakness) |